Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LPL | P06858 | 3/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31394505 | 0.87 | LPL (0.39) | MAPK1LPLLIPGROCK1P2RX7 | |
| SCHEMBL25425149 | 0.79 | MAPK1 (0.35) | MAPK1 | |
| SCHEMBL30716028 | 0.78 | KDM4E (0.36) | MAPK1 | |
| SCHEMBL25425144 | 0.78 | KDM4E (0.36) | MAPK1 | |
| SCHEMBL26323113 | 0.77 | LPL (0.34) | MAPK1LPLLIPGROCK1 | |
| SCHEMBL31394217 | 0.77 | LPL (0.38) | MAPK1LPLLIPGROCK1P2RX7 | |
| SCHEMBL4998784 | 0.75 | LPL (0.39) | LPLLIPGROCK1P2RX7 | |
| SCHEMBL16336538 | 0.75 | MAPK1 (0.45) | MAPK1LPLLIPGROCK1P2RX7 | |
| SCHEMBL31001988 | 0.75 | MAPK1 (0.41) | MAPK1LPLLIPGROCK1P2RX7 | |
| SCHEMBL20451563 | 0.75 | MAPK1 (0.41) | MAPK1LPLLIPGROCK1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10106504-B2 | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2018-10-23 | — | — | US | disclosed |
| US-20180222864-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-08-09 | — | — | US | disclosed |
| EP-3337798-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017029631-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222864-A1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | TYMP, TYMS, DUT | MAPK1 1028/4885LPL 4631/4885LIPG 4153/4885 |
| US-10106504-B2 | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | TYMP, TYMS, DUT | MAPK1 1028/4885LPL 4631/4885LIPG 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.